Northeast Pharmaceutical Group Co., Ltd. (000597.SZ)
- Previous Close
5.19 - Open
5.18 - Bid 5.28 x --
- Ask 5.29 x --
- Day's Range
5.18 - 5.36 - 52 Week Range
3.72 - 6.69 - Volume
32,721,781 - Avg. Volume
24,451,935 - Market Cap (intraday)
7.546B - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
18.86 - EPS (TTM)
0.28 - Earnings Date --
- Forward Dividend & Yield 0.10 (1.93%)
- Ex-Dividend Date May 23, 2024
- 1y Target Est
--
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals preparations, pharmaceutical business, pharmaceutical engineering, biomedicine, and other businesses in China. It offers vitamin products, including vitamin C, vitamin B1, vitamin B6, and levocarnitine series; anti-infection products, such as fosfomycin series, azithromycin series, berberine hydrochloride, chloramphenicol, and other products; and reproductive system and sex hormone products comprising carboprost suppositories, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. The company also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; narcotics and narcotic-containing products, including morphine hydrochloride injection, pethidine hydrochloride injection, morphine hydrochloride tablets, oxycodone hydrochloride injection, and other products; anti-AIDS products comprising kedu/zidovudine tablets, kedu/zidovudine capsules, efavirenz tablets, zidolamid bivudine tablets, and other products; and in vitro biological diagnostic reagent products, such as HIV, HBV, HCV, HPV, and TB molecular diagnostic reagents. In addition, it offers general health products, including vitamin C powder, effervescent tablets, chewable tablets, solid drinks, glycosaminoglycan chondroitin sulfate collagen D3 calcium capsules, protein powder, probiotic powder, and other products. Further, the company provides Zhengchangsheng aluminum carbonate magnesium chewable tablets; Zhenxiwei compound proglumide and cimetidine tablets; amlodipine maleate; compound licorice series; narcotine syrup; Kefei, a compound codeine phosphate syrup; Xiaoke, a citronix tablets; acetaminophen tablets, pain-relieving tablets; metronidazole tablets; tinidazole tablets; paracetamol tablets; and other products. Additionally, it engages in medical distribution business. The company was founded in 1946 and is based in Shenyang, China.
www.nepharm.com.cn5,964
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000597.SZ
View MorePerformance Overview: 000597.SZ
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000597.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000597.SZ
View MoreValuation Measures
Market Cap
7.55B
Enterprise Value
6.29B
Trailing P/E
19.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.00
Price/Book (mrq)
1.41
Enterprise Value/Revenue
0.84
Enterprise Value/EBITDA
10.45
Financial Highlights
Profitability and Income Statement
Profit Margin
5.17%
Return on Assets (ttm)
1.86%
Return on Equity (ttm)
7.36%
Revenue (ttm)
7.51B
Net Income Avi to Common (ttm)
388.54M
Diluted EPS (ttm)
0.28
Balance Sheet and Cash Flow
Total Cash (mrq)
3.39B
Total Debt/Equity (mrq)
38.03%
Levered Free Cash Flow (ttm)
-1.66B